<DOC>
	<DOCNO>NCT00050765</DOCNO>
	<brief_summary>MyoCell™ implantation epicardial injection CABG surgery potential add new dimension management post-infarct deterioration cardiac function . Based exist non-clinical study clinical report , implantation autologous skeletal myoblasts appear lead replacement non-functioning myocardial scar function muscle appear improve myocardial performance relative case without myoblast implantation . In investigational patient , myoblast implantation , , do conjunction CABG appear potential provide additive treatment surgery . The present study conduct evaluate fully safety MyoCell™ implantation via epicardial injection CABG surgery effect regional myocardial function .</brief_summary>
	<brief_title>Autologous Cultured Myoblasts ( BioWhittaker ) Transplanted Via Myocardial Injection</brief_title>
	<detailed_description>MyoCell™ mediate cellular cardiomyoplasty novel therapeutic approach management progressive heart failure patient damage myocardial tissue result myocardial infarct . MyoCell™ consist patient autologous skeletal myoblasts expand ex vivo supply cell suspension buffer salt solution injection area damage , akinetic myocardium goal myoblasts populate implant area generate elastic , contractile skeletal muscle-like tissue within damage myocardium . Because physiological goal replace inelastic , fibrous myocardial scar tissue skeletal muscle-like tissue , originate cellular implant , therapeutic approach term `` cellular cardiomyoplasty '' `` CCM '' . The purpose trial ass safety MyoCell™ ( expand autologous skeletal myoblasts ) use dose escalation methodology follow epicardial injection myocardial scar tissue patient experience anterior , lateral , posterior inferior wall myocardial infarction , require coronary artery bypass graft ( CABG ) surgery implantable cardioverter defibrillator ( ICD ) place ( ICD implant CABG procedure 3 4 day post CABG procedure ) . Safety endpoint evaluation nature frequency Adverse Events 12-month period follow MyoCell™ treatment . If patient meet baseline enrollment criterion , 5-10 gram skeletal muscle biopsy obtain myoblast isolation expansion vitro Bioheart 's designate facility MyoCell™ production . Biopsy occur 3 - 4 week prior anticipate implantation MyoCell™ product . At time patient 's CABG surgery MyoCell™ inject akinetic myocardial scar region previous infarct utilize sterile hypodermic syringe fit 25 gauge needle . This dose escalation study 3 cohort group consist 5 patient . A report 1 month safety data cohort present data safety monitor board permission go next high dosage . In first cohort dose escalation study ; 2 injection perform , second cohort ; 6 injection third cohort ; 18 injection depend size infarct scar , inject entire myocardial infarct scar akinetic area .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Defined region myocardial dysfunction relate previous myocardial infarction involve anterior , lateral , posterior inferior wall , &gt; 12 week old scheduled time MyoCell™ implantation procedure Patients must implantable cardioverter defibrillator ( ICD ) place , patient must receive ICD placement CABG procedure 3 4 day CABG procedure Planned CABG procedure revascularization Heart failure patient New York Heart Association Symptom Class 2 3 optimal medical therapy Age &gt; 18 &lt; 80 year Able undergo surgical biopsy skeletal muscle successful culture harvest myoblasts Target region wall thickness &gt; 6 mm echocardiography Left ventricular ejection fraction &gt; 20 % &lt; 40 % radionuclide ventriculography leave ventricular angiography screen If female childbearing potential , urine pregnancy test must negative Able give write informed consent Patient medically unable undergo CABG surgery Any patient document myocardial infarction ( ECG change elevate cardiac enzyme consistent MI ) within 30 day schedule surgical revascularization cellular implantation procedure . Known sensitivity gentamicin sulfate and/or amphotericinB Exposure investigational drug procedure within 4 week prior study entry The use expect use antineoplastic drug History skeletal muscle disease , either primary ( i.e. , myopathy ) secondary ( i.e. , ischemic ) underlie myopathy myasthenia gravis , muscular dystrophy , etc . ) determine board certify pathologist examine sample patient muscle biopsy Previous angiogenic therapy and/or myocardial laser therapy History cancer within 5 year , except basal cell carcinoma skin PSA suggestive carcinoma prostate ( i.e. , &gt; 4 ) Patient CEA &gt; 2.5 ng/mL end stage renal disease Patients active infectious disease and/or know test positive HIV , HTLV , HBVsAg , HCV , CMV and/or syphilis . If panel include antibody HBc HBVsAg , expert consult . Females pregnant nursing . Females childbearing potential must use investigator 's satisfaction , medically accept method birth control ( e.g. , limited , oral implant contraceptive therapy intrauterine device ) agree continue duration study . Any illness might affect patient ’ survival study followup period Any illness , Investigator ’ judgment , interfere patient ’ ability comply protocol , compromise patient safety , interfere interpretation study result . Patient previous cardiac surgery Patient valvular disease great mild degree consider primary cause heart failure Patient New York Heart Association Symptom Class 1 4 Patient serum creatinine &gt; 2.5 No informed consent unable provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Heart disease</keyword>
	<keyword>Coronary bypass graft ( CABG ) surgery</keyword>
	<keyword>Implantable Cardioverter Defibrillator ( ICD )</keyword>
	<keyword>CABG</keyword>
	<keyword>ICD</keyword>
	<keyword>Heart failure</keyword>
</DOC>